GlaxoSmithKline News and Research

RSS

Nabi Biopharmaceuticals completes sale of PentaStaph vaccine candidate to GSK

Nabi Biopharmaceuticals announced today that it has successfully completed the technology transfer of program know-how associated with the sale of the PentaStaphTM vaccine candidate to GlaxoSmithKline Biologicals S.A.. As a result of successfully completing this milestone, Nabi is eligible to receive $8 million under the agreement governing Nabi's sale of PentaStaphTM (Pentavalent S. aureus Vaccine) and related assets to GSK.

11 Aug 2010

Psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019: Pharmacor 2010

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

ASEBIO to host Biospain 2010

The Spanish Bioindustry Association (ASEBIO), in collaboration with the Navarre Society of Development (SODENA), and the government of Navarre, will host BioSpain 2010 the biennial international gathering of experts in the biotechnology sector, in Pamplona from September 29th to October 1st. BioSpain 2010 is honoured to welcome three lecturers of international prestige: Mr. Carlos Cordon-Cardo, Vice-Chair of Pathology & Professor, Columbia University; Mr. Larry Fritz, President & CEO, Covella Pharmaceuticals Inc. and Life Science Venture Partner, Westfield Capital Management Company LP; and Mr. Conny Bogentoft, CEO Karolinska Development AB.

8 Aug 2010

Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010

Nabi Biopharmaceuticals today announced its second quarter financial results for the three month period ended June 26, 2010. The Company reported a net loss from continuing operations of $3.4 million, or $0.08 per share, compared to a net loss of $5.8 million, or $0.11 per share, for the period ended June 27, 2009.

6 Aug 2010

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

Scientists to develop new antibiotics to tackle infection-causing bacteria

Detailed pictures published today reveal how a new type of experimental antibiotic can kill bacteria that are already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

5 Aug 2010

Amplimmune collaborates with GSK to develop PD-1 targeting therapies

Amplimmune, Inc. today announced that it has entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to AMP-224 as well as other potential next generation fusion proteins that target PD-1.

5 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

Emerging Healthcare Solutions executes Term Sheet with Stand-By Systems

Emerging Healthcare Solutions, Inc. disclosed today that the Company has executed a Term Sheet with Stand-By Systems. The Term Sheet represents successful negotiations between the two companies just ahead of finalizing a Definitive Agreement. Stand-By Systems (SBS) owns the FDA approved SBS 1615 catalytic oxygen generator and associated systems. This cutting edge generator provides medical grade USP oxygen at the push of a button from self-contained inert dry compounds.

3 Aug 2010

FDA announces approval of vaccines for 2010-2011 US influenza season

The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States.

31 Jul 2010

IQPC's Polymorphism & Crystallization Scientific Forum to address issues on polymorphs

There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC's Polymorphism & Crystallization Scientific Forum, taking place October 25- 27, 2010 in Philadelphia, PA will address these issues.

31 Jul 2010

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

GlaxoSmithKline announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.

30 Jul 2010

ISMPP and MPIP initiative launches new web page

On July 29, 2010 the International Society for Medical Publication Professionals (ISMPP) and the Medical Publishing Insights and Practices (MPIP) initiative launched a new web page highlighting various MPIP initiatives (http://www.mpip-initiative.org). The web page is a valuable resource providing information on the overall MPIP initiative, updating viewers on new or planned activities, and providing access to previous MPIP publications and resources.

30 Jul 2010

GSK exercises option to obtain exclusive licence to develop, commercialise GSK '052

Anacor Pharmaceuticals and GlaxoSmithKline PLC today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK '052), formerly known as AN3365. GSK '052 is a novel, systemic antibiotic derived from Anacor's boron chemistry platform.

30 Jul 2010

Isis Pharmaceuticals receives $5M payment from GSK for dug development

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Aptuit announces strategic partnership Siena Biotech

Aptuit, Inc., and Siena Biotech S.p.A., today announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech's development pipeline. Under the agreement Aptuit and Siena Biotech will work collaboratively on the development of Siena Biotech's pipeline of compounds, focused in three key therapeutic areas, including Alzheimer's disease, Huntington's disease and oncology.

29 Jul 2010